Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Inclusion Criteria

• Age:
• 16 years old in Module 1 (US only: ≥18year)
• 12 years old in Module 2
• Diagnosis: Known Diagnosis of CD22-positive B-ALL based on criteria established by WHO (Alaggio et al. 2022).
• Participants must have relapsed or refractory B-ALL ('relapsed' defined as bone marrow blasts > 5% or reappearance of blasts in PB)
• Module 1 (DE): Ph(-) B-ALL and Ph(+) B-ALL - R/R
• Backfill of Module 1 and Module 2 (DO): R/R Ph(-) B-ALL
• Performance status (ECOG ≤ 2; KPS ≥ 50; LPS ≥ 50)
• Peripheral lymphoblast count < 10,000/µL (may receive cytoreduction prior to C1D1 per protocol-specified criteria)
• At least 2 prior therapies with refractoriness or relapse, or 1 prior therapy with refractoriness or relapse and no standard options available. Participants who have received prior CD22 targeted therapies are eligible.
• Ph+ B-ALL (Module 1 DE only): intolerant to or have contraindications to TKI therapy or R/R disease despite treatment with at least 2 prior TKIs or at least one 3rd generation TKI
• Prior DLI >4 weeks, prior cell therapy or autoHSCT >8 weeks, alloHSCT >12 weeks

Exclusion Criteria

• Burkitt lymphoma and leukemia
• Isolated extramedullary disease; Active testicular or CNS (> CNS1) involvement
• Unresolved non-heme toxicities Grade ≥ 2 (except alopecia, stable Grade ≤ 2 neuropathy, vitiligo, endocrine disorders controlled with therapy)
• History of drug-induced non-infectious ILD/pneumonitis requiring oral or IV steroids or supplemental oxygen or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
• Prior/concomitant therapy
• Cytotoxic treatment within 14 days (except ALL maintenance medications or cytoreduction)
• Biologic (immuno-oncology) treatment within 28 days or 5 half-lives (whichever is shorter)
• Non-CNS radiation within 2 weeks & CNS radiation within 4 weeks
• Medications known to prolong QTc and/or associated with Torsades de Pointes within 5 half-lives
• Strong inhibitors of CYP 3A4 within 14 days or 5 half-lives (whichever is longer)
• Investigational agents or study interventions in the last 30 days or 5 half-lives prior to the first dose of AZD4512 whichever is longer. If the investigational product is an agent to treat B-ALL and meets the modality criteria, then a specific washout period must be adhered to instead.